Unity Biotechnology
UBX was delisted on the 8th of July, 2025.
39 hedge funds and large institutions have $4.66M invested in Unity Biotechnology in 2024 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 7 increasing their positions, 11 reducing their positions, and 7 closing their positions.
8,000% more call options, than puts
Call options by funds: $81K | Put options by funds: $1K
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
0.78% less ownership
Funds ownership: 21.34% → 20.55% (-0.78%)
3% less funds holding
Funds holding: 40 → 39 (-1)
14% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 7
21% less capital invested
Capital invested by funds: $5.87M → $4.66M (-$1.22M)
36% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$50.7K |
| 2 |
Morgan Stanley
New York
|
+$24K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$22.6K |
| 4 |
UOC
UBS O'Connor
Chicago,
Illinois
|
+$2.41K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$2.12K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$64.3K |
| 2 |
Millennium Management
New York
|
-$41.4K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$38K |
| 4 |
BlackRock
New York
|
-$36.4K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$32.5K |
UBX Hedge Fund Activity: Q2 2024 in Review
39 of the 6,935 institutional investors tracked by Wall St. Rank reported a position in Unity Biotechnology (UBX) for Q2 2024, worth a combined $4.66M — down 21% from $5.87M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of UBX and 6 opened new positions — a net loss of 1 holder — while 11 trimmed existing stakes and 7 added.
The largest buyer was Vanguard Group, adding an estimated $50.7K. The largest seller was Renaissance Technologies, cutting an estimated $64.3K.
- 39 institutional investors held Unity Biotechnology (UBX) as of Q2 2024, down from 40 in Q1 2024.
- Funds reported $4.66M of Unity Biotechnology stock for Q2 2024, down 21% quarter-over-quarter.
- 6 funds opened new Unity Biotechnology positions in Q2 2024 and 7 closed out, a net change of -1 holder.
- The largest Unity Biotechnology buyer in Q2 2024 was Vanguard Group, an estimated $50.7K added.
- The largest Unity Biotechnology seller in Q2 2024 was Renaissance Technologies, an estimated $64.3K sold.
Based on aggregated 13F filings for Q2 2024.